Business
Merit Medical Systems manufactures interventional and diagnostic medical devices.
Merit Medical Systems grew revenue, remained profitable, generated positive free cash flow at a 12.2% operating margin. Capital spending and stock compensation grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 11.8%OK
- Profitability — Net income grew 6.8% to $128.489M from $120.357MOK
- Cash flow — Free cash flow grew 16.2% to $215.655M from $185.659MOK
- Margins — Operating margin expanded 71 bps to 12.19%OK
- Accounting — Capital spending and stock compensation grew faster than revenueNote
- Insiders — 5 purchases and 8 salesOK
Where the revenue comes from
Fiscal 2025, as MERIT MEDICAL SYSTEMS INC reports it. History and quarterly detail are in the app.
- Cardiovascular$1.4B
- Endoscopy$72.9M
Leadership changes
From MERIT MEDICAL SYSTEMS INC's own filings, the day they're filed.
- Martha G. Aronson · CEO · departureeff. 2025-10-03
- Joseph C. Wright · President · departureeff. 2025-01-03
- Fred P. Lampropoulos · Chief Executive Officer · departureeff. 2024-05-15
Latest filings
- 8-K · Company announcement2026-08-20
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-30
- 8-K · Company announcement2026-05-19
- 8-K · Company announcement2026-04-30
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about MERIT MEDICAL SYSTEMS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.